Celldex Therapeutics (NASDAQ:CLDX) Given "Buy" Rating at HC Wainwright

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $80.00 price objective on the biopharmaceutical company's stock. HC Wainwright's target price would suggest a potential upside of 336.44% from the stock's previous close.

Several other equities research analysts also recently weighed in on the stock. UBS Group initiated coverage on shares of Celldex Therapeutics in a research note on Thursday, February 13th. They set a "buy" rating and a $44.00 target price for the company. Canaccord Genuity Group began coverage on Celldex Therapeutics in a research report on Monday, April 28th. They set a "buy" rating and a $64.00 price objective for the company. Morgan Stanley initiated coverage on Celldex Therapeutics in a report on Thursday, March 20th. They issued an "overweight" rating and a $46.00 target price on the stock. The Goldman Sachs Group lowered their price objective on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating on the stock in a research report on Monday, March 3rd. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $53.90.

Celldex Therapeutics Trading Down 6.1 %

NASDAQ:CLDX traded down $1.19 during midday trading on Tuesday, hitting $18.33. 1,001,538 shares of the company were exchanged, compared to its average volume of 889,846. Celldex Therapeutics has a fifty-two week low of $14.40 and a fifty-two week high of $47.00. The company has a market capitalization of $1.22 billion, a PE ratio of -7.13 and a beta of 1.39. The company has a fifty day simple moving average of $18.99 and a 200 day simple moving average of $22.84.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The firm had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.08 million. As a group, equities research analysts expect that Celldex Therapeutics will post -2.48 EPS for the current year.

Institutional Trading of Celldex Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Values First Advisors Inc. raised its position in shares of Celldex Therapeutics by 20.0% during the 4th quarter. Values First Advisors Inc. now owns 29,009 shares of the biopharmaceutical company's stock worth $733,000 after purchasing an additional 4,837 shares during the last quarter. Barclays PLC raised its holdings in shares of Celldex Therapeutics by 140.7% in the third quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company's stock worth $4,431,000 after acquiring an additional 76,207 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of Celldex Therapeutics by 24.4% in the fourth quarter. SG Americas Securities LLC now owns 25,283 shares of the biopharmaceutical company's stock valued at $639,000 after acquiring an additional 4,967 shares in the last quarter. Invesco Ltd. lifted its position in shares of Celldex Therapeutics by 2.1% in the fourth quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company's stock valued at $1,064,000 after acquiring an additional 871 shares in the last quarter. Finally, Sovran Advisors LLC acquired a new stake in shares of Celldex Therapeutics during the fourth quarter valued at $2,867,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.